恩曲他滨 | 1238210-10-0

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 核苷和核苷酸类似物
• 中文名称: 恩曲他滨
• 英文名称: Emtricitabine Carboxylic Acid
• 英文别名: (2R,5S)-5-(4-amino-5-fluoro-2-oxopyrimidin-1-yl)-1,3-oxathiolane-2-carboxylic acid
• CAS: 1238210-10-0
• 化学式: C₈H₈FN₃O₄S
• 分子量: 261.23
• InChiKey: GQHACZWRCOKKIZ-MHTLYPKNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  131
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• PROCESS FOR PRODUCING 5-FLUORO-1-(2R, 5S)-[2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL]CYTOSINE
  申请人：Tyagi Om Dutt

  公开号：US20100256372A1

  公开（公告）日：2010-10-07

  Disclosed herein an improved process for producing 5-Fluoro-1-(2R,5S)-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine and its pharmaceutical acceptable salts.

  本文披露了一种生产5-氟-1-(2R,5S)-[2-(羟甲基)-1,3-噁嗪-5-基]胞嘧啶及其药用可接受盐的改进工艺。
• Process and intermediates for preparing emtricitabine
  申请人：Bertolini Giorgio

  公开号：US20060189805A1

  公开（公告）日：2006-08-24

  A process is disclosed for the stereo-selective preparation of emtricitabine, which allows the desired product to be obtained in good yield and without the use of chromatographic techniques. The process for the production of emtricitabine of the formula (Ia) is characterized by the formation and isolation of intermediate compounds of formula (XIa) in salified form. Emtricitabine is a known antiviral drug.

  本发明公开了一种立体选择性制备恩曲他滨的方法，该方法允许以良好的产率获得所需的产物，且不需要使用色谱技术。该制备恩曲他滨的方法的特点在于形成和分离盐化形式的式(Ⅺa)的中间化合物。恩曲他滨是一种已知的抗病毒药物。
• Process and Intermediates for Preparing Emtricitabine
  申请人：BERTOLINI Giorgio

  公开号：US20090192310A1

  公开（公告）日：2009-07-30

  A novel process for preparing emtricitabine, and more particularly a process for preparing emtricitabine involving the formation and isolation of intermediate compounds in salified form, is described.

  本发明涉及一种制备恩曲他滨的新工艺，更具体地说，涉及一种制备恩曲他滨的工艺，其中包括以盐化形式形成和分离中间化合物的步骤。
• PROCESS FOR NUCLEOSIDES
  申请人：Reddy Bandi Parthasaradhi

  公开号：US20140046062A1

  公开（公告）日：2014-02-13

  The present invention relates to improved process for the preparation of lamivudine or emtricitabine. Thus, (1′R,2′S,5′R)-menthyl-5(R,S)-acetoxy-[1,3]-oxathiolane-2(R)-carboxylate is reacted with N-propinoyl cytosine in hexamethyl disilazane and then added trityl perchlorate to obtain a solid containing (1′R,2′S,5′R)-menthyl-5S-(N-4″-propionylcytosin-1″-yl)-[1,3]-oxathiolane-2R-carboxylate. The solid obtained above is reacted with methane sulfonic acid to obtain (2R,5S)-5-(4-amino-2-oxo-2H-pyrimidin-1-yl)-[1,3]-oxathiolane-2-carboxylic acid, 2S-isopropyl-5R-methyl-1R-cyclohexyl ester. The above compound is reduced with sodium borohydride to obtain lamivudine.

  本发明涉及一种改进的拉米夫定或恩替卡韦的制备方法。因此，将（1'R，2'S，5'R）-薄荷基-5（R，S）-乙酰氧基-[1,3]-噁唑烷-2（R）-羧酸酯与N-丙烯酰胞嘧啶在六甲基二硅氮烷中反应，然后加入三苯甲酰氯酸盐以得到固体，其中包含（1'R，2'S，5'R）-薄荷基-5S-（N-4″-丙酰基胞嘧啶-1″-基）-[1,3]-噁唑烷-2R-羧酸酯。上述固体与甲烷磺酸反应，得到（2R，5S）-5-（4-氨基-2-氧代-2H-嘧啶-1-基）-[1,3]-噁唑烷-2-羧酸，2S-异丙基-5R-甲基-1R-环己基酯。上述化合物用硼氢化钠还原，得到拉米夫定。
• Process for producing Lamivudine and Emtricitabine
  申请人：Nelson Mandela Metropolitan University

  公开号：US10815223B2

  公开（公告）日：2020-10-27

  This invention provides for flow and batch synthesis processes for the production of Lamivudine and Emtricitabine, including flow and batch synthesis processes wherein at least of the synthesis steps are conducted in a solvent free environment.

  本发明提供了生产拉米夫定和恩曲他滨的流程式和批量式合成工艺，包括至少有一个合成步骤是在无溶剂环境中进行的流程式和批量式合成工艺。